stockrowMaravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
Follow MRVI
Alert me
Maravai LifeSciences Holdings, Inc. (MRVI) Gross margin
Maravai LifeSciences Holdings, Inc.'s gross margin over the twelve months to 30 September 2026 was 39.2%, up 20.8 percentage points from fiscal 2025 (18.3%). Over the past ten years it has ranged from 18.3% (fiscal 2025) to 82.4% (fiscal 2021) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 68.5% and below the Healthcare sector median of 54.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 18.3% | (23.49) |
| FY2024 | 41.8% | (6.73) |
| FY2023 | 48.5% | (32.35) |
| FY2022 | 80.9% | (1.54) |
| FY2021 | 82.4% | 10.45 |
| FY2020 | 72.0% | 18.66 |
| FY2019 | 53.3% | 2.37 |
| FY2018 | 50.9% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 35.3% | (4.83) |
| Jun 2026 | 40.1% | (11.05) |
| Mar 2026 | 51.2% | 25.44 |
| Dec 2025 | 25.8% | 12.17 |
| 24 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| VIR Vir Biotechnology, Inc. compare | 100.0% |
| HRMY Harmony Biosciences Holdings, Inc. compare | 74.0% |
| MRVI Maravai LifeSciences Holdings, Inc. | 39.2% |
| SRPT Sarepta Therapeutics, Inc. compare | 0.00% |
| REPL Replimune Group, Inc. compare | 0.00% |
| TRVI Trevi Therapeutics, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | −269.7% |
| MAZE Maze Therapeutics, Inc. compare | — |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
| Biotechnology industry median | 68.5% |
| Healthcare sector median | 54.5% |
| Market median | 46.0% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue